Advanced Enzyme Technologies (NSE:ADVENZYMES) Cyclically Adjusted Revenue per Share: ₹57.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ADVENZYMES Advanced Enzyme Technologies Ltd NSE:ADVENZYMES
88 GF Score
Price ₹296.00
GF Value ₹411.35
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Advanced Enzyme Technologies Cyclically Adjusted Revenue per Share?

Advanced Enzyme Technologies NSE:ADVENZYMES -0.83% 88 Cyclically Adjusted Revenue per Share is ₹57.41 as of Jun. 2026. GuruFocus rates NSE:ADVENZYMES with a GF Score™ of 88/100 and a GF Value™ of ₹411.35 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Advanced Enzyme Technologies's adjusted revenue per share for the three months ended in Jun. 2026 was ₹16.936. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹57.41 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Advanced Enzyme Technologies's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-03), Advanced Enzyme Technologies's current stock price is ₹296.00. Advanced Enzyme Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹57.41. Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio of today is 5.16.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Advanced Enzyme Technologies was 10.62. The lowest was 4.83. And the median was 6.20.


Advanced Enzyme Technologies  (NSE:ADVENZYMES) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=296.00/57.41
=5.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Advanced Enzyme Technologies was 10.62. The lowest was 4.83. And the median was 6.20.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Advanced Enzyme Technologies Cyclically Adjusted Revenue per Share Related Terms


Advanced Enzyme Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Advanced Enzyme Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Enzyme Technologies Cyclically Adjusted Revenue per Share Chart

Advanced Enzyme Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 49.66 51.72 56.00

Advanced Enzyme Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.80 54.25 55.03 56.00 57.41

NSE:ADVENZYMES vs LIN, SHW, ECL: Cyclically Adjusted Revenue per Share Comparison

For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Enzyme Technologies Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio falls into.


NSE:ADVENZYMES
88GF Score
Advanced Enzyme Technologies Ltd NSE:ADVENZYMES
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Enzyme Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Advanced Enzyme Technologies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.936/167.3573*167.3573
=16.936

Current CPI (Jun. 2026) = 167.3573.

Advanced Enzyme Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 8.140 105.961 12.856
201612 5.245 105.196 8.344
201703 7.656 105.196 12.180
201706 6.984 107.109 10.912
201709 8.846 109.021 13.579
201712 9.687 109.404 14.818
201803 9.689 109.786 14.770
201806 9.351 111.317 14.059
201809 9.217 115.142 13.397
201812 9.114 115.142 13.247
201903 9.704 118.202 13.739
201906 9.876 120.880 13.673
201909 9.973 123.175 13.550
201912 10.027 126.235 13.293
202003 9.651 124.705 12.952
202006 9.873 127.000 13.010
202009 10.781 130.118 13.866
202012 12.307 130.889 15.736
202103 11.774 131.771 14.954
202106 12.233 134.084 15.269
202109 11.369 135.847 14.006
202112 11.906 138.161 14.422
202203 11.753 138.822 14.169
202206 10.843 142.347 12.748
202209 12.383 144.661 14.326
202212 12.697 145.763 14.578
202303 12.409 146.865 14.140
202306 13.189 150.280 14.688
202309 14.129 151.492 15.609
202312 14.408 152.924 15.768
202403 14.047 153.035 15.362
202406 13.800 155.789 14.825
202409 13.037 157.882 13.819
202412 15.093 158.323 15.954
202503 14.962 157.552 15.893
202506 16.622 159.755 17.413
202509 16.483 162.289 16.998
202512 15.334 163.281 15.717
202603 18.177 164.272 18.518
202606 16.936 167.357 16.936

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹57.41 mean?
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a Cyclically Adjusted Revenue per Share of ₹57.41 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced Enzyme Technologies and its competitors.
Is Advanced Enzyme Technologies' Cyclically Adjusted Revenue per Share too high?
Advanced Enzyme Technologies' current Cyclically Adjusted Revenue per Share is ₹57.41. Overall, Advanced Enzyme Technologies has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' Cyclically Adjusted Revenue per Share compare to LIN and SHW?
Advanced Enzyme Technologies' Cyclically Adjusted Revenue per Share of ₹57.41 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Chemicals company?
A good Cyclically Adjusted Revenue per Share depends on the Chemicals industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced Enzyme Technologies and its competitors. Advanced Enzyme Technologies's current Cyclically Adjusted Revenue per Share is ₹57.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹411.35, compared to a current price of ₹296.00 — trading 28% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹57.41. Advanced Enzyme Technologies' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current Cyclically Adjusted Revenue per Share is ₹57.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued. The current stock price of ₹296.00 is trading 28% below its estimated GF Value™ of ₹411.35. GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.

Key valuation signals for NSE:ADVENZYMES:

  • Cyclically Adjusted Revenue per Share: ₹57.41
  • GF Value™: ₹411.35 vs. price of ₹296.00 (28% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Advanced Enzyme Technologies Business Description

Other Exchanges 540025:India
Address Near LIC Service Road, Sun Magnetica, A Wing, 5th Floor, Louiswadi, Thane (West), Thane, MH, IND, 400604
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
88GF Score

Get the complete analysis for NSE:ADVENZYMES

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹296.00
Price
₹411.35
GF Value